

-
- (1) COMPLETION OF THE ACQUISITION OF (A) 40% STAKE IN YOMA SILOAM HOSPITAL PUN HLAING LIMITED AND (B) 35% STAKE IN PUN HLAING INTERNATIONAL HOSPITAL LIMITED; AND
 - (2) CHANGE IN AND UPDATE ON THE USE OF PROCEEDS FROM PLACEMENT OF 562,500,000 NEW ORDINARY SHARES IN THE SHARE CAPITAL OF OUE LIPPO HEALTHCARE LIMITED
-

1. INTRODUCTION

The Board of Directors (the "**Board**") of OUE Lippo Healthcare Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to:

- (a) the announcements released by the Company in relation to the proposed acquisition of 40% stake in Yoma Siloam Hospital Pun Hlaing Limited and 35% stake in Pun Hlaing International Hospital Limited (the "**Proposed Transaction**") dated 10 January 2019 and the approval by shareholders of the Company for the Proposed Transaction dated 28 January 2019 (collectively, the "**Acquisition Announcements**");
- (b) the announcements released by the Company in relation to the issuance of 562,500,000 new ordinary shares in the share capital of the Company pursuant to a placement agreement entered into with Brownly Healthcare Pte. Ltd. (the "**Placement**") dated 10 January 2018, 12 February 2018, 19 February 2018, 12 April 2018 and 3 October 2018 (collectively, the "**Placement Announcements**"), and the change in and update on the use of the net proceeds from the Placement dated 14 March 2018 (the "**Change In and Use of Proceeds Announcement**"); and
- (c) the Company's annual report for the financial year ended 31 December 2018 despatched to shareholders on 3 April 2018 (the "**Annual Report**").

Capitalised terms used herein shall have the definitions ascribed to them in the Acquisition Announcements, the Placement Announcements and the Annual Report, unless otherwise stated or the context otherwise requires.

2. COMPLETION OF THE PROPOSED TRANSACTION

Further to the Acquisition Announcements, the Board is pleased to announce that the Proposed Transaction has been completed today. Accordingly, OHS and OHA now hold 40% of the total number of shares in the capital of YSHPH and 35% of the total number of shares in the capital of PHIH respectively.

3. CHANGE IN AND UPDATE ON THE USE OF PROCEEDS FROM PLACEMENT

Further to the Placement Announcements, the Change In and Use of Proceeds Announcement and the Annual Report, the Board wishes to provide an update on the reallocation and use of the net proceeds from the Placement of approximately S\$77.45 million (the “**Placement Net Proceeds**”).

The Company wishes to announce that S\$12,700,000 of the Placement Net Proceeds allocated for development of healthcare business and healthcare related projects following the Change In and Use of Proceeds Announcement has been allocated towards general working capital to fund the Group’s working capital requirements.

In light of the completion of the Proposed Transaction, funds from the Company may be required for the working capital needs of YSHPH and PHIH. Accordingly, the Board is of the view that such reallocation of the Placement Net Proceeds is in the best interests of the Company and its shareholders as the reallocated Placement Net Proceeds would be better utilised for the general working capital of the Group (which now includes YSHPH and PHIH).

As at the date of this announcement, the reallocation and use of the Placement Net Proceeds are as follows:

Use of Placement Net Proceeds	Amount allocated under the Change In and Use of Proceeds Announcement (S\$'000)	Amount allocated pursuant to the reallocation (S\$'000)	Amount utilised (S\$'000)	Amount unutilised (S\$'000)
Repayment of loans & borrowings	26,000	26,000	26,000	-
General working capital ⁽¹⁾	11,450	24,150	15,450	8,700
Development of healthcare business and healthcare related projects	40,000	27,300	27,300	-
Total	77,450	77,450	68,750	8,700

Note:

- (1) Utilised mainly for payroll, bank interests, legal and other professional fees, and other corporate expenditures.

The Company will make further announcement(s) on the use of the remaining Placement Net Proceeds as and when they are materially disbursed.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
24 April 2019

This announcement has been prepared by the Company and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”), for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).